Professional Background:
Lucas rejoined Alacrita as a Partner with a focus on investor relations, venture capital engagement, and supporting biotech companies within the portfolios of leading life sciences investors. He brings a strong track record of executive leadership, strategic fundraising, and business development across the biotech innovation landscape.
Prior to returning to Alacrita, Lucas served as Chief Business Officer and subsequently Chief Executive Officer at Doloromics, a precision medicine company pioneering novel therapeutics for chronic pain. During his tenure, he led corporate strategy, investor engagement, and partnership development, advancing Doloromics’ position at the forefront of pain research and precision neuroscience.
Earlier in his career, Lucas was the Co-Founder and CEO of CerSci Therapeutics, where he guided the company through the acquisition of its lead program, IND-enabling studies, Phase I trials, and ultimately through its successful acquisition by Acadia Pharmaceuticals (NASDAQ: ACAD). His experience spans the full lifecycle of biotech company development, from scientific and operational execution to corporate transactions.
Lucas previously worked with Alacrita as a Consultant, contributing deep operational insight from the startup biotech environment across therapeutic areas including oncology, CNS, pain, metabolic disorders, liver disease, and cardiovascular disease.
He holds a BS in Biology with a minor in Chemistry from Baylor University, and an MS and PhD in Biomedical Engineering from The University of Texas at Dallas.
Education:
- The University of Texas at Dallas, PhD in Biomedical Engineering, 2016
- Design and Development of Improved Dental Abutment for Cement-Retained Crowns
- The University of Texas at Dallas, MS in Biomedical Engineering, 2014
- Development of Bioactive Bone Cements for Orthopedic and Craniofacial Surgery
- Baylor University, BS in Biology, Minor in Chemistry
Awards, Recognitions & Fellowships:
- Distinguished Alumni Award - The University of Texas at Dallas (2021)
- EY Entrepreneur of the Year Nominee (2020)
- BIO International Opioid Working Group Member
- Dallas Innovates Innovator of the Year 2019
- NEXT Award - Entrepreneurship and Innovation
- University of Texas at Dallas Honor Society
- Fellow of the Texas Biomedical Device Center
- Baylor University Interdisciplinary Core Honors College
BACK
